Method for achieving desired glial growth factor 2 plasma levels
AssigneeAcorda Therapeutics, Inc.
InventorsHaesun Kim, Anthony O. Caggiano
Life of this patent
Estimating the term…
Abstract
The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or disorder associated with reduced levels of myelination and the GGF2 is administered to promote myelination in the patient.
Claims10
1-18. (canceled)
A method for broadening the therapeutic dose range for glial growth factor 2 (GGF2) when GGF2 is used to facilitate myelination, the method comprising:
- selecting a subject with a disease or disorder associated with reduced levels of myelination;
- administering GGF2 and a Mek1/Erk pathway inhibitor to the patient, and, whereby GGF2-mediated myelination is occurs at higher doses of GGF2 than would occur in the absence of administering the Mekl/Erk pathway inhibitor.
A method for determining if an amount of GGF2 is a therapeutically effective amount for promoting myelination, the method comprising:
- providing a subject receiving GGF2 therapy;
- and
- measuring c-Jun protein levels in the subject, whereby an increase in c-Jun relative to baseline c-Jun levels indicates that the amount of GGF2 is near a maximum threshold of therapeutic efficacy for promoting myelination.
27-28. (canceled)
Dependencies are inferred from the claim text.